CHARLESTON, SOUTH CAROLINA

October 27-29, 2021

WILD DUNES HOTEL • ISLE OF PALMS

ATTENDEE LISTS

SPEAKERS

President, Health Platforms, Verily Life Sciences

Vivian Lee

Chief Operating Officer, Mammoth

Kim Mackrill

Head Eastern North America, Johnson & Johnson Innovation

Dr. Michal Preminger

CEO of BioIQ

Sean Slovenski

Vice President of Global Public Heallth at Johnson & Johnson

Pierre Theodore

Founder and CEO, BiotechExec

Russell Allen

Kathryn Cole Becker

President & Founder – Life Science Partner

Tom Callaway

Partner – HealthQuest Capital

Todd Creech

CEO, TeleHealth

Robert L. Crutchfield

CEO & Co-Founder Strados Labs

Nick Delmonico

Partner, Hatteras Venture Partners

Mike Dial, PhD

Managing Director, Silicon Valley Bank

Julie Ebert

Audit Partner, Hughes Pittman & Gupton

Thomas Fagley

Director of Business Development at TriLink

May Gou

VP, Team Lead, Medical Device at Within3

Kim Hale

Partner, Nelson Mullins

Christopher Hanson

Director, Patient Engagement & Advocacy; Clinical Trial Diversity at Moderna

Jameka Hill

Lillia Holmes

Product Realization Program at GCMI

Saylan Lukas

Co-founder & CEO, VRYTY

Eugene Luskin

Tina McKeon, Board Chair
Partner Kilpatrick Townsend

Tina McKeon

Director – Life Sciences, Silicon Valley Bank

Scott McCarty

womens-board-jayne-morgan
Director of Cardiovascular Research – Piedmont Heart Institute

Jayne Morgan, Co-Chair

Founder and CEO of Radyus Research

Marta New

CMO, One World Health

Edward O’Bryan

Partner, Hutchison PLLC

Dan O’Korn

SVP, Research, Ribometrix

Manjunath “Manju” Ramarao, Ph.D.

Managing Director at Middleland Capital

James Ramey

Director of Regulatory Affairs, Proxima Clinical Research

Isabella Schmitt

Paul Snyder

Director of Corporate Development, Cumberland Emerging Technologies

Jim Stefansic

Principal – The Pinnacle Group

David White

President, Health Platforms, Verily Life Sciences

Vivian Lee

Vivian S. Lee, M.D., Ph.D., M.B.A., is the author of The Long Fix: Solving America’s Health Care Crisis with Strategies that Work for Everyone (Norton). She is President of Health Platforms at Verily Life Sciences. A physician and health care executive, Lee also serves as a senior lecturer at Harvard Medical School.

Prior to joining Verily, Lee served as the Dean of the Medical School and CEO of the University of Utah Health Care, an integrated health system with a budget of $3.6 billion, including a 1400 member physician group and health insurance plan. During her tenure, she led University of Utah Health to recognition for its health care delivery system innovations that enable higher quality at lower costs and with higher patient satisfaction, and superior financial performance. In 2016, University of Utah was ranked first among all university hospitals in quality and safety (Vizient).  Dr. Lee previously was the inaugural Chief Scientific Officer of New York University’s Langone Medical Center.

Elected to the National Academy of Medicine with over 200 peer-reviewed publications, Lee serves on the Board of Directors of the Commonwealth Fund, the Board of Trustees of Boston Children’s Hospital, and is also a director on the board of Zions Bancorporation, a publicly traded company.

Dr. Lee is a magna cum laude graduate of Harvard, received a D.Phil in medical engineering from Oxford University as a Rhodes Scholar, earned her M.D. with honors from Harvard Medical School, and her MBA from NYU. She was named by Modern Healthcare as one of the 50 Most Influential Clinical Executives in 2020.

Chief Operating Officer, Mammoth

Kim Mackrill

Kim serves as the organizational integrator at Mammoth with a strong
focus toward aligning the interests of the investment adviser, fund
manager, investors, and portfolio company founders.
Kim creates efficient processes to conceptualize and develop compelling
solutions for the problems facing businesses and their customers. She
leverages her deep know-how to help portfolio companies integrate
data and technology to help them deliver proprietary experiences to
their customers. Kim also leverages her operational expertise to allow
Mammoth lean operations, better aligning our interests with Fund
Members.
Kim began her career in the nonprofit world and moved to a publicly
traded company in 2005 where she coordinated joint marketing across a
global sales team. In 2009, Kim opened a boutique design firm and began
building technology and experiences for concierge medicine and wealth
management firms.
In 2015, Kim co-founded Mineral Interactive. Kim led operations and
strategy for the firm, creating marketing campaigns and digital products
for many of independent wealth management’s leading fintech and
wealth management brands. Kim’s work won multiple awards and
eight of her portfolio companies went on to successful acquisitions and
recapitalizations.
Kim achieved a strategic exit when Mineral was acquired by Carson
Group in 2018, where Kim went on to lead marketing and client
experience design. Her work there included an enterprise rebrand
and ensured the design and delivery of a complete end to end digital
experience across 100+ national offices and 30,000+ retail investors.
Kim graduated summa cum laude from Grace University in Omaha (BA).
She grew up around the world through her family’s various stops as part
of the assignments with the United States Air Force including Germany,
Washington DC, Hawaii and Omaha.

Head Eastern North America, Johnson & Johnson Innovation

Dr. Michal Preminger

Michal is Head of Johnson & Johnson Innovation, East North America, located at the Innovation Centre in Boston. In this role she leads the Innovation Center team to build, advance, and manage the External R&D portfolio of co-investments spanning across pharmaceutical, consumer health and medical devices.
Until recently, Michal served as the Executive Director of Harvard University’s Office of Technology Development (OTD) Harvard Medical School site, where she was responsible for development and commercialization of technologies emerging from research at HMS laboratories and for the strategy and execution of all industry collaborations. She negotiated agreements with major biopharma, life sciences, food and cosmetics companies to advance the translation of discoveries into products and create a revenue-generating product pipeline, and worked with scientific founders and investors to create new startup companies.
Prior to joining Harvard University’s OTD in 2005, Michal held a number of business development and technology development positions at Compugen, most recently as VP of Protein Therapeutics, responsible for the business management of the company’s emerging drug discovery pipeline. Previously, she worked in the technology industry in marketing and business development roles, and co-founded a biotechnology startup.
Michal serves on the Scientific Advisory Boards FutuRx Accelerator, and was, until recently, a member of the SAB of Prize4Life and a Member of the Board of Directors of a number of companies, including Compugen and Alma Lasers.
She holds a Ph.D. in Biological Sciences from the Weizmann Institute of Science, an MBA from INSEAD, Fontainebleau, France, and a BA in Medicine from Hadassah Medical School, Hebrew University, Jerusalem.

CEO of BioIQ

Sean Slovenski

Sean Slovenski is recognized as a healthcare industry innovator with a 30-year history of success. Slovenski is a proven senior executive and entrepreneur with an established track record in small, medium, and large-scale businesses.

Slovenski started his career by helping to build and then lead one of the nation’s first large-scale wellness efforts for Fortune 500 clientele. Envisioning the widespread usage of the Internet, Sean pioneered the development and delivery of wellness coaching online by inventing the first-of-its kind personal coaching product, MyHealthCoach.com. This effort led to being a co-founder and the CEO of the industry leading coaching company Hummingbird Coaching Services. Hummingbird was acquired by Humana, Inc. in July 2010.

Slovenski also adds to his credit the development and operations for two of the largest health system based Integrative Medicine and Wellness centers in the US, The Mercy Centers for Health & Wellness located in Cincinnati, Ohio as well as being the CEO of the international joint venture between Humana and Discovery Health of South Africa to create one of the largest and most proven wellness incentive companies in the industry.

Slovenski served as the CEO of Care Innovations, an Intel-GE joint venture in the telehealth and remote patient monitoring space.

Getting back to his wellness roots, Slovenski then took on reinventing the industry-leading population health company as the President of Population Health at Healthways, which Slovenski sold to ShareCare In 2016.

Most recently Slovenski served as the SVP and president of Walmart Health and Wellness. This business serves nearly half of all Americans each year through its 4,700 pharmacies, 2,800 optical centers, and the newly launched multi-disciplinary healthcare clinics known as the “Supercenters for Healthcare.”

Slovenski has the honor of being named Healthcare Leader of the Year by the US Chamber of Commerce in 2015 and 2019 as the 7th most influential person in healthcare out of the top 100 by Modern Health Magazine.

Slovenski resides in Cincinnati with his wife and daughter.

Vice President of Global Public Heallth at Johnson & Johnson

Pierre Theodore

Pierre R. Theodore is a Thoracic Surgeon and Vice President of Global Public Heallth at Johnson & Johnson.  He is responsible to help accelerate novel technologies to advance the standard of care in the surgical management of patients worldwide.  Dr. Theodore is on the adjunct surgical faculty of Stanford Medical Center.

He has over two decades of experience in cardiothoracic surgery, surgical education, innovation with a particular focus on Global Surgery initiatives to expand surgical capacity in low- and middle-income countries.

Pierre received undergraduate education at Princeton and his Doctor of Medicine from the University of Virginia.  He completed general surgical and cardiothoracic surgical training at Johns Hopkins Hospital and a post-doctoral fellowship at the Massachusetts General Hospital Transplant Biology Research Center, Harvard Medical School.

Founder and CEO, BiotechExec

Russell Allen

Appointed GRA’s third president in September 2018, Russell Allen is an established leader in Georgia’s life sciences industry who built a career on starting new enterprises, unifying different sectors and championing economic growth.

For nearly six years, Allen served as president and CEO of Georgia Bio, the voice for Georgia’s life sciences industry. He engineered and led the strategy that grew membership and deepened member engagement to make the organization a more effective advocate for the industry. During his tenure, Georgia Bio expanded its education and workforce development program, strengthened partnerships between companies and universities and launched the Bio/Med Investor Network to help early-stage companies bridge funding gaps.

Allen began his career selling laboratory equipment after graduating Pepperdine University with a degree in biology. He worked briefly in his home state of Mississippi, then moved to Georgia in 1994. This was in the early days of the Internet, and Allen learned all he could about the emerging technology. In 1996, he launched one of the nation’s first digital marketing and web development agencies, Newton Park, ultimately growing it into one of Atlanta’s top 5 Internet agencies.

Following the dot-com boom, Allen launched another technology marketing firm, iQuotient, with a division dedicated to serving bioscience and healthcare companies. Around the same time, he served on a biotech task force for the Metro Atlanta Chamber. The group’s work laid the foundation for a major new initiative to develop and promote Georgia’s bioscience industry – and in 2002, Allen became the Metro Chamber’s first vice president of an industry-focused area, biosciences.

While at the Metro Chamber, Allen co-founded BioSouth, a unique enterprise that connected the southeastern life science industry with international researchers and companies. Its signature BioFusion conference opened doors to new relationships between the region and the rest of the world.

Allen was recruited in 2006 to lead BioFlorida, the state’s bioscience industry association, and for much of his time there Florida was the nation’s fastest-growing bioscience state. He left Florida in 2013 to head GeorgiaBio.

Allen serves on a dozen boards and industry councils and recently chaired the U.S. Council of State Bioscience Associations. In addition to his undergraduate degree, he holds a certificate in biotech enterprise management from Vanderbilt University.

Kathryn Cole Becker

Kathryn Becker established Charleston, SC-based Translational Science Solutions LLC in 2014 to facilitate the commercialization of innovative medical device and digital health products at all stages of development. She utilizes her in-depth knowledge of science, regulatory affairs, business planning, and product management to develop, coordinate, and execute business-minded regulatory strategies that help clients anticipate, meet and exceed FDA regulatory requirements. Services include the analysis of complex regulatory challenges, development of regulatory strategies for new products, and the preparation and stewardship of related submissions and interactions with FDA on behalf of clients. 

President & Founder – Life Science Partner

Tom Callaway

Tom is a venture partner with HealthQuest, where he leverages his training as a physician, experience in the diagnostics industry and success as one of the industry’s best executive recruiters and management team builders. He serves as a Board observer for portfolio companies Lineagen and Inmediata.

Tom founded Life Science Partner, a very successful executive recruiting firm that has helped build the leadership teams at some of the world’s foremost medical device and pharmaceutical companies, as well as many venture-backed companies in the medical device, biotech and healthcare services sectors. Prior to LSP, he led similar practices at Korn/Ferry and Russell Reynolds. Tom has learned that the quality of a company’s management team predicts its success more than products or technologies and that perspective guides him in looking at companies for HealthQuest.

Tom began his career at Roche Molecular, where he developed and implemented their first marketing programs around PCR for medical diagnostics, including HIV detection. Like all HealthQuest partners he then worked inside a start-up, SyStemix where he established technology developmental partnerships with major cancer centers including MD Anderson, Fred Hutchinson Cancer Research Center and the Mayo Clinic. SyStemix developed proprietary stem cell purifying technologies important for treatment of cancer and genetic illnesses. He was the liaison with Sandoz’s oncology group, whose parent company completed its acquisition of the company in 1996.

Tom has been especially active at promoting the industry across his home state of Georgia and the entire southeast. He is former Chairman of Georgia Bio, co-founder of SEMDA, the Southeast Medical Device Association and serves on the boards of SEBIO and the Parker H. Petit Institute for Bioengineering and Bioscience at Georgia Tech.

Tom earned his MD from Vanderbilt and both his undergraduate degree and MBA from Duke University. He lives with his wife and two daughters in Atlanta. He splits his free time between hiking and skiing in the mountains and kite-boarding on the coast.

Partner – HealthQuest Capital

Todd Creech

Todd has spent the last nine years as a healthcare CFO, helping build several successful companies to profitable exits. He joins HealthQuest excited to bring his operations and financial experiences to innovative companies that are primed for growth with the right plan and execution.

For the last year, he has been the acting CFO for Femasys, a medtech company developing and selling devices targeted at women’s health issues. Prior to that, he was CFO and Treasurer of ZS Pharma (IPO in 2014 and sold to AstraZenaca in 2015; a 30x increase in valuation from when he joined in 2013).  Todd was the CFO and led business development activities for Sarcode which developed lifitigrast, the first dry-eye pharmaceutical to be approved (2016) for both signs and symptoms of dry eye (sold to Shire in 2013).  He was also the CFO of Sirion Therapeutics, an ophthalmic company that successfully developed and received approval for two products (Durezol and Virgan) and sold to Alcon and Bausch and Lomb in 2010. During his CFO tenure he has raised more than $500m in equity and debt, helping to build operations and companies that generated over $3.5b in exits.

Earlier in his career, Todd did healthcare venture investing for Quintiles and worked with SRI International. He has also co-founded two companies; a spectroscopy platform spinout of Duke University (Centice) and a specialty pharmaceutical company (TLC Pharma).

Todd holds bachelor’s degrees in Finance and Accounting from Miami (Ohio) University where he was also a scholarship baseball player, and an MBA from Duke University. He is an Executive-in-Residence for Moffitt Cancer Center and sits on the Healthcare Advisory Board for Duke’s Fuqua School of Business. He and his wife live in Tampa, Florida with their two sons.

CEO, TeleHealth

Robert L. Crutchfield

Telehealth Solution is the leading telehealth provider services company providing healthcare services to the post-acute and rural acute healthcare markets. Today, enabled by a robust technology platform, we are delivering best practice patient care clinical services with high quality compliance and client services. TeleHealth is providing the right care at the right time coverage to patients in over 200 hospitals, skilled nursing facilities and ISNIPs. TeleHealth Solution is currently able to practice in all 50 states.

Prior to TeleHealth, Bob launched and led the American Cancer Society’s strategic venture philanthropy platform, BrightEdge, targeting investments in advanced therapies to treat, detect, and prevent all types of cancer. While there he made four investments: Castle Biosciences – a provider of a diagnostic test for uveal and cutaneous melanoma that also identifies patients with the highest risk for metastasis, Freenome – a blood-based, multi-analyte screening test for colorectal cancer, Navigating Cancer – a healthcare IT company focused on helping cancer patients remain compliant and adherent to their oncology treatment programs and Tmunity – a CART-T immuno-oncology company.  He served as a board observer to Castle Biosciences prior to their NASDAQ listing in July, and currently services as a board observer for Freenome, Navigating Cancer and Tmunity.

 Prior to the BrightEdge Fund, Bob was a Sr. Partner at Harbert Growth Partners where he led the healthcare practice. While there, he served as a board member or board observer on Shipt – acquired by Target in 2017, Wellcentive – acquired by Royal Philips in 2016, nContact – acquired by Atricure in 2014 and Novamin – acquired by GSK in 2009, along with other portfolio companies he helped manage.

 His other professional roles include serving as the Executive Director of Innovate Birmingham, an 18-month initiative to assess, evaluate and make recommendations to Birmingham’s economic development organizations on strategies for accelerating the growth of that market’s technology-based economy.  During this time, he also served as an Operating Advisor to Harbert Growth Partners, after stepping down as the Senior Partner and Healthcare Practice Leader in 2017. Prior to Harbert he was Vice President/General Manager of the Pharmacy Services Division at US Oncology, a privately held, vertically integrated cancer care provider network, that sold to McKesson in 2010. Prior to US Oncology, he was a Senior Executive at Cardinal Health where he served as Vice President/General Manager of New Ventures. Prior to Cardinal he was the founder and CEO of Surgical Innovations & Services, Inc. (SIS). 

 He also serves on the Board of Trustees of the Georgia Research Alliance, the boards of Southeast Life Sciences, the Southern Capital Forum, the Atlanta Global Center for Medical Innovation and HealthSouth Connect.

 Bob is a graduate of the University of Georgia and holds Bachelor of Science degrees in Political Science and Chemistry.

CEO & Co-Founder Strados Labs

Nick Delmonico

Nick Delmonico is the founder & CEO of Strados Labs, a medical technology company focused on creating novel ways to manage and monitor respiratory health. As an asthma patient, he believed there was a better way to communicate symptoms to doctors using wearable technologies to avoid bad outcomes. Prior to founding Strados Labs, he worked in various financial and consulting roles including PwC and J.P Morgan Chase & Co. During his MBA in Fox School of Business at Temple University, he worked at ECG (now part of Siemens Healthineers), where he served the general health strategy sector. He holds a Certified Public Accounting license in New York State, and is an active board member of the American Lung Association in Philadelphia, PA. He was named to the Millennials to Watch in Life Sciences list 2018 by Philadelphia Business Journal, a Be Your Own Boss Bowl prize winner in both 2016 (2nd place) and 2017 (1st and Grand Prize) as well as a WeWork Creator Award Finalist.

Partner, Hatteras Venture Partners

Mike Dial, PhD

Experienced investor and scientist. Mike has over a decade of experience working with early-stage life science and healthcare companies. Mike joined Hatteras in 2009 from Silicon Valley Bank, where he was a Vice President in the Corporate Finance Group focused on emerging tech and life science companies and venture capital funds. Prior to SVB, he held research scientist positions in the Department of Biochemistry at UNC-Chapel Hill, the Laboratory of Structural Biology at the National Institute of Environmental Health Sciences, and the UNC-Duke Michael Hooker Proteomics Center. He has performed research in the fields of cell cycle regulation, proteomics, and cancer therapy.

Mike is a Professor of the Practice at the Kenan-Flagler Business School at The University of North Carolina at Chapel Hill and is the Manager for the Carolina Research Ventures Fund, a $10M fund dedicated to UNC-Chapel Hill related start-ups. He holds a Ph.D. in Biochemistry and Biophysics from UNC-Chapel Hill.

Mike serves on the boards of Ribometrix, StrideBio, and Genturi. Previously, Mike was involved with G1 Therapeutics, Viamet, Lysosomal Therapeutics, Artizan Biosciences, and Curoverse among others, and has held various operational roles in Hatteras portfolio companies. Mike has also served on committees and panels for the North Carolina Biotech Center, Council for Entrepreneurial Development, SEBIO and PTP NEXT. Mike serves on the board of SE BIO.

Managing Director, Silicon Valley Bank

Julie Ebert

Audit Partner, Hughes Pittman & Gupton

Thomas Fagley

Tom is currently the leader of the Firm’s life science practice and has 24 years of experience, 18 in public accounting and six in private practice.  He started his career at PricewaterhouseCoopers as an audit associate.  Tom was previously a controller and CFO with a sports travel company.  Tom joined Hughes Pittman & Gupton, LLP in November 2006, and became a partner in January 2014.

Tom works with both public and nonpublic companies.  Tom’s primary focus is life science clients.  In addition to being an audit partner, Tom provides interim chief financial officer services to private companies and SEC reporting services for public companies.  Tom has experience with biotechnology, pharmaceutical, medical device, contract research organizations, software, professional services, distribution, and venture capital funds.

Director of Business Development at TriLink

May Gou

May is the Director of Business Development at TriLink, helping customers to accelerate their mRNA product development. She as over 15 years of experience in the life science industry, gained knowledge of the drug discovery process while working for Promega, learned about immune-oncology and cell therapy while at Agilent, learned about CRISPR gene editing while at Synthego. She likes to bring solutions to customers and connect people in the industry, with her knowledge of the mRNA industry, product design and manufacturing process. May received her bachelor’s degree in Chemistry from Peking University and MBA from Georgetown University.

VP, Team Lead, Medical Device at Within3

Kim Hale

Kim Hale is a medical device and life science professional with extensive experience in customer satisfaction, strategic planning, and business consultation. He has 29 years of experience helping life science companies recognize and implement technology strategies that make a meaningful impact on their business.

In his role as VP, Team Lead for Medical Device at Within3, Kim helps medical device, pharmaceutical and biotech companies create better patient outcomes by implementing digital strategies that improve internal and external collaboration.

Partner, Nelson Mullins

Christopher Hanson

Christopher is the head of the FDA Regulatory Compliance & Litigation Group at Nelson Mullins. Based in Greenville, South Carolina, he assists clients in tackling their most sophisticated and high-stakes regulatory issues involving medical devices, in vitro diagnostics (IVDs), human and animal drugs, and clinical laboratories. He has aided clients in consequential interactions with federal, state, and foreign regulatory agencies, including the U.S. Food and Drug Administration (FDA), the Centers for Medicare & Medicaid Services (CMS), and the Federal Trade Commission (FTC).

In his advisory practice, Christopher crafts creative and practical solutions for clients. His work includes drafting FDA and CLIA regulatory submissions as well as preparing public comments for agency rulemakings, guidance documents, advisory committees, and public policy venues. He provides strategic advice and regulatory due diligence to support corporate transactions and securities filings in the life sciences space. He also has experience counseling in agency enforcement matters and conducting global internal investigations and audits. During the COVID-19 pandemic, Christopher has supported several medical device manufacturers and clinical laboratories in drafting Emergency Use Authorization (EUA) submissions for COVID-19 diagnostic tests.

A prolific writer and frequent speaker in industry, academic, and government-sponsored settings, he is the author of “Overview of the Legal Framework for Medical Device Regulation in the United States” in Practising Law Institute’s Medical Devices Law and Regulation Answer Book (2021, 2019). Christopher received his undergraduate degree from Yale University, a master’s degree from Harvard University, and his law degree from Northwestern University.

Director, Patient Engagement & Advocacy; Clinical Trial Diversity at Moderna

Jameka Hill

Lillia Holmes

Product Realization Program at GCMI

Saylan Lukas

Saylan Lukas leads the Product Realization Program at Global Center for Medical Innovation (GCMI), an affiliate of Georgia Institute of Technology in Atlanta, GA. He has over 15 years of medical device design and development experience at large multi-national corporations and startup companies. Saylan has led project teams from initial feasibility through global commercialization in areas of craniomaxillofacial implants and instruments, transcatheter heart-valve stent grafts and delivery systems, cranial stabilization systems, cancer diagnosis and treatment devices, and laparoscopic instruments. Saylan has Mechanical and Biomedical engineering degrees from Rose-Hulman Institute of Technology and an MBA from Butler University.

Co-founder & CEO, VRYTY

Eugene Luskin

Over 12 years of CEO experience out of 20+ total years in software/firmware/hardware development industry. A computer science graduate from the University of Haifa (Israel), his technology background includes variety of roles at large companies such as Microsoft, Intel and Parametric as well as advisory and executive positions at several startups.

Prior to founding VYRTY Corporation, as a Chairman and CEO of Lagotek Corporation, he successfully managed the company for 7 years from inception, building a uniquely assembled team, releasing multiple versions of the software platform and over 10 hardware product lines, managing international manufacturing processes, steadily growing revenue numbers and structuring multiple funding rounds. Eugene has multiple issued and pending patents.

During 7 years spent at Microsoft, Eugene’s responsibilities ranged from developing core parts of MS OLAP Server to managing processes and projects of designing, releasing and deploying a companywide data instrumentation, collection and ingestion platforms, driving cross team adoption with multiple engineering and marketing departments, working closely with legal, security and privacy professionals to receive compliance certifications in accordance with the US and International regulations and coping with the increasingly sophisticated demands of data producers and consumers while maintaining high levels of data availability and reliability.

While at Intel, Eugene was Leading development, implementation and project structure definitions of tools for inductance calculation in microprocessors, including screening, extraction, scan-line based and other algorithms.

Tina McKeon, Board Chair

Partner Kilpatrick Townsend

Tina McKeon

Dr. McKeon contributes her talent and time to a number of bioscience and medical device organizations. She has served on the boards of Southeast Bio and Metro Atlanta Red Cross and is the current co-chair of Southeast Life Sciences. From 2005 until 2016, she taught in the TI:GER® Program, a collaboration between Emory University School of Law and Georgia Institute of Technology, that focuses on technology commercialization in a multidisciplinary context. She is also a frequent lecturer regarding the role of intellectual property in entrepreneurship and has served as adjunct faculty at Emory Law School. Dr. McKeon is the author of more than 14 scientific publications.

Dr. McKeon was named an “Atlanta Lawyer of the Year” in 2018 for Biotechnology Law and in 2012 for Patent Law by The Best Lawyers in America®. She was also listed in The Best Lawyers in America® for Patent Law and Biotechnology and Life Sciences Law in 2020 and each of the 11 years immediately preceding. Dr. McKeon has been recognized annually since 2009 by Chambers USA: America’s Leading Lawyers, which stated she “has a respected postdoctoral academic background and is highly regarding for her ‘great depth of knowledge’, particularly in biotech matters.” Dr. McKeon was named a Georgia “Super Lawyer” in 2020 and each of the 12 years immediately preceding, a “Top 50 Women Georgia Super Lawyer” in 2019 and each of the six years immediately preceding, and a “Top 100 Georgia Super Lawyer” in 2016 by Super Lawyers magazine. She is a recipient of the 2019 SEBIO Leadership Award  and the 2013 Georgia Bio Community Award. Dr. McKeon was recognized by Georgia Bio for “being that rare combination of scientific expertise, legal acumen and sociability that affords her a broad role in the Georgia life sciences community.” She was named one of the “Top 10 IP Stars of the Top 250 Women in IP” in 2013 and 2016 and recognized as an “IP Star” in 2019 and the six years immediately preceding by Managing Intellectual Property magazine. Dr. McKeon was named as one of Georgia Trend‘s 2018 “Legal Elite” for Intellectual Property Law. She was named a top patent practitioner in 2014-2019 by IAM Patent 1000 – The World’s Leading Patent Practitioners. Dr. McKeon was named by Legal Media Group in its 2014 and 2016-2019 Expert Guide to the World’s Leading Women in Business Law. She was selected as a “Life Science Star” in the 2016 edition of LMG Life Sciences. Dr. McKeon is AV Preeminent® rated by Martindale-Hubbell.*

Director – Life Sciences, Silicon Valley Bank

Scott McCarty

Scott is currently working as a Director on the National Life Sciences Team for SVB, covering the Mid-Atlantic and Southeast markets. Through his 12 years with Silicon Valley Bank based in the Atlanta office, Scott has been focused on providing specialized banking and lending services to the innovation economy with specific focus on growing the Bank’s healthcare practice. Previous to SVB, Scott was a sales executive for an emerging healthcare IT company. Scott graduated from the University of Georgia with a major in Finance from the Terry College of Business.

womens-board-jayne-morgan

Director of Cardiovascular Research – Piedmont Heart Institute

Jayne Morgan, Co-Chair

Dr. Jayne Morgan is a Cardiologist with extensive experience in clinical patient management, as well as pharmaceutical and biotech research. For the past 2 decades she has focused on improving the care and quality of life measures for patients from heterogenous populations, including end-of-life patients without further medical options.

Serving in the roles of both Clinical Development and Medical Affairs for global pharmaceutical and device companies for the past 10 years, she has successfully led Phase II and III programs globally, and Phase IV programs in Europe. In these roles, her background includes leadership and accountability for research projects with oversight of a $52 million dollar budget within a $4.5 billion company.

As the driver of the cardio-renal and heart failure programs (sponsored and funded by Solvay Pharmaceuticals), and providing the scientific guidance as a consultant to the MitraClip programs (funded and sponsored by Abbott Vascular), her experience in the design and execution of large international clinical trials for both devices and pharmaceuticals is well established. Acknowledged with both the Solvay Cardio-Metabolic Strategic Paper Award and People to People Ambassadorship for vulnerable global populations, she has selected and led many scientific panel experts including Steering Committees, Adjudication Committees, and Data Safety Monitoring Board Committees, and has also served on regulatory panels for both the FDA and EMA.

Following high school graduation as Valedictorian, Dr. Morgan went on to complete her B.S. degree in Biology and Biochemistry from Spelman College; her M.D. degree from Michigan State University; Internal Medicine Residency from George Washington University; and Cardiology Fellowship at Mount Sinai Medical Center including completion of a Pacemaker Sub-Fellowship. She has treated patients in both rural primary care settings, as well as within academic institutions as the Associate Professor of Medicine at the Cleveland Clinic Florida, and is published in both the American Heart Journal and recognized by the Heart Failure Society for her work on Adenosine Receptor Antagonists. Further, Dr. Morgan has received numerous distinctions in Principles of Radiation Physics, and RadioPharmaceuticals and Chemistry in Nuclear Medicine. In fact, most recently, she served as the CMO (Chief Medical Officer) of the American Chemistry Council where she introduced new stakeholders, advocated for senate bill reforms, and developed a strategy and new direction for their research program including securing funding from the Board of $5 million dollars annually for 4 years.

Dr. Morgan has also served as a 6 year Board member of the Make-A-Wish Foundation of Georgia and Alabama and the Calvary Childrens Home (orphanage). Currently, she is a Founding Member of Biotechnology for Women, member of the AHA (American Heart Association), AMA (American Medical Association), AWMA (American Womens Medical Association), and the ABC (Association of Black Cardiologists). Additionally, she is recognized as an Industry Fellow for the GRA (Georgia Research Alliance) focused on the development and commercialization of biotech and pharma innovations into viable companies and partnerships here in the state of Georgia.

Currently, she is the Director of Cardiovascular Research at the Piedmont Research Institute where she is responsible for all drug, device, and drug/device combination trials in both the Cardiovascular and Peripheral Vascular space. Bringing to an organization over 20+ years of clinical and industry experience, and a demonstrated record of strategic planning, management, and execution of trials to support the medical and scientific platform of an organization, Dr. Morgan is able to leverage a wealth of qualifications in business development, scientific rigor/conduct, medical education, and communication.

Founder and CEO of Radyus Research

Marta New

Marta is the founder and CEO of Radyus Research, a preclinical drug development contract research organization based in Atlanta, GA. Before founding Radyus in 2019, Marta was the co-founding Partner at Agent Capital, LLC, a life sciences-focused venture capital firm based in Cambridge, MA. While at Agent, Marta participated in multiple venture capital investments in oncology, immunology and rare disease areas including Orchard Therapeutics (NASDAQ:ORTX), Precision Biosciences (NASDAQ:DITL), Pliant Therapeutics and Verge Genomics, among others. Prior to Agent Capital,  Marta was a Principal investor at Baxalta Ventures, the corporate venture capital arm of Baxalta in Cambridge MA, where she participated in multiple venture capital investments and served as a board observer for Gadeta BV (acquired by Kite/Gilead, 2018), Syntimmune (acq. by Alexion, 2018), and Vitesse Biologics (early stage accelerator funded by Baxalta, Mayo Clinic and Velocity Pharmaceutical Development).

Marta started her investment career at Baxter Ventures, the corporate venture capital arm of Baxter in Chicago, IL, transitioning from the Global Renal Marketing franchise, where she was the commercial lead for multiple new products for the Chinese and European markets. She joined Baxter from Northwestern University’s Innovation and New Ventures Office where she was responsible for licensing negotiations, commercial assessment of patents, and industry alliance management.

Marta received her PhD from the University of Illinois at Chicago in microbiology and immunology and completed her post-doctoral training at Northwestern University. She also received an MBA from Northwestern University Kellogg School of Management in Chicago, IL.

CMO, One World Health

Edward O’Bryan

Partner, Hutchison PLLC

Dan O’Korn

Dan’s practice focuses on the business transactions important to pharmaceutical and biotech companies, including licensing and commercial transactions, FDA-related regulatory matters, asset acquisitions and divestitures, supply agreements, product development agreements and strategic alliances. Dan previously served as outside counsel to life sciences companies and in in-house counsel roles for Eli Lilly and Company, AAIPharma, Inc., Xanodyne Pharmaceuticals, Inc. and Xcellerex, Inc.

SVP, Research, Ribometrix

Manjunath “Manju” Ramarao, Ph.D.

Manju has more than 20 years of experience biopharmaceutical research and development senior management and portfolio management.

Most recently, Manju held a senior executive position at the Biocon-Bristol-Myers Squibb R&D Center, BBRC, in Bangalore, India. He served as an executive director, site leader for research, and early development and head of discovery biology and translational medicine with responsibility for scientific strategy, a wide range of preclinical programs and platforms, and management of the large R&D organization. Research under his oversight spanned multiple therapeutic areas, including oncology, immunology, fibrosis, and cardiovascular disease. Manju joined BMS (BBRC) at its inception in 2009, and in close collaboration with Bristol-Myers Squibb, BMS, U.S., he was instrumental in building a world class research center with state-of-the-art capabilities and talent recruited from across the world.

Prior to his roles at BMS, Manju worked for eight years at Pfizer, Wyeth, in Cambridge, MA, leading biology programs in immunology and pain.

Manju received his B.Sc. and M.Sc. from Bangalore University, India, and his M.S. and Ph.D. from the University of Illinois. His post-graduate experience included a post-doctoral fellowship and an instructor position at Harvard Medical School.

Managing Director at Middleland Capital

James Ramey

James Ramey is a Managing Director and Fund Manager at Middleland Capital where he manages VTC Ventures. VTC Ventures invest in high growth Seed, Series A, and Series B-stage companies across the country, the Commonwealth of Virginia, and within the broader Virginia Tech, Carilion, and Roanoke / Blacksburg ecosystem. Prior to joining Middleland Capital, James was a Vice President at Tyton Partners, a leading ed-tech investment banking firm located in the greater New York City area. James’ unique background, which includes practicing law, investment banking, and prior venture capital experience, provides a holistic and multi-faceted approach to venture capital investing.

Director of Regulatory Affairs, Proxima Clinical Research

Isabella Schmitt

Isabella Schmitt is the Director of Regulatory Affairs at Proxima Clinical Research, Inc. , a contract research organization focusing on assisting emerging medical device and biotech companies in regulatory, quality, and clinical development. At Proxima, Isabella is responsible for overseeing over 100+ medical device and pharma projects. Prior to joining Proxima, Isabella served as the Senior Regulatory and Quality Manager for two medical device companies, where she outlined the regulatory strategy and put together design controls and quality documentation, and as the Director of CMC and Quality at a biopharmaceutical company, where she oversaw all product development and ensured CMC regulatory strategy was sufficient for filings the US and Europe.

Outside of Proxima, Isabella is a judge, mentor, and speaker for multiple healthcare accelerators, including MedTech Innovator, TMCx, MassChallenge, gBEta, and Hatch.  She also serves as a pitch coach for SXSW Pitch Competition.

Paul Snyder

Paul has served as the director of the Write2Market heathcare practice since 2013. Write2Market is an Atlanta based digital marketing and public relations firm. He has twenty years of experience on the front lines of fresh, effective communication strategies that build businesses. He has 15 years of experiencing leading teams to communication successes in an agency setting. Before joining W2M, Paul was Director of Development for the business school at Mercer University, where he was responsible for fundraising and board development. He graduated from Ohio Wesleyan University with a degree in economics.

In a previous life, Paul was a golf professional and played as a full-time pro. He’s also an avid trout angler and founding member of the bluegrass band Whoa Nelly (2001).

Director of Corporate Development, Cumberland Emerging Technologies

Jim Stefansic

Jim Stefansic is the Director of Development at Cumberland Emerging Technologies (CET). His responsibilities include sourcing, evaluating, and negotiating for new biopharmaceutical product and technology opportunities, in addition to contributing to the management and expansion of CET’s university collaborations.

 

Stefansic was previously COO of Pathfinder Therapeutics, Inc., a company he co-founded, where he led FDA regulatory submissions and business development activities. While there, he raised more than $17 million in venture capital and Small Business Innovation Research (SBIR) funding. He also previously served as the director of commercialization at Launch Tennessee, where he was instrumental in leading the acquisition of funding to develop and support the statewide SBIR program.  He earned an undergraduate degree in biomedical engineering from Johns Hopkins University, a doctorate from Vanderbilt, and his MBA from Belmont University’s Jack C. Massey Graduate School of Business, where he currently serves as an adjunct professor of business and was named the distinguished alumnus of the year in 2011. Stefansic started his career as a research professor at Vanderbilt University Medical Center. He was also co-founder and CEO of Raiven Healthcare.

Principal – The Pinnacle Group

David White

David is a principal and founding member of MRC Global, the result of a merger between Pinnacle and MRCx, and serves as a member of the leadership team where he directs growth strategies for the organization including service line expansion and new company development. Known as a creative thinker and problem solver, David’s professional focus is geared toward building stronger provider relationships and identifying shared business opportunities.

With more than 25 years’ experience in health care organization management and consulting, David’s expertise is extensive and includes new business development, health services valuation and financial analysis, health care market research, medical staff partnership planning, and physician practice management consulting.

David has managed thousands of fair market value analyses for a broad array of clients located across the country including health systems, medical device/pharmaceutical companies, community/rural hospitals, specialty health service providers, and single/multi-specialty medical groups. He has also worked with national health plans on provider contracting and medical management issues and is viewed as a leading expert in the dialysis industry with more than 18 years’ experience as a valuation and management consultant.

In addition to his leadership role with Pinnacle, David has been part of management teams developing and launching a wide variety of services including urgent care access and delivery, outsourced medical coding solutions, telemedicine technology and support services, an insurance brokerage offering tailored provider solutions, and an insightful approach to credentialing for physician thought leadership.

Prior to Pinnacle, David was a health care consultant with Milliman USA and a co-founder of Physician and Hospital Solutions. He also served as Director of Planning and Practice Management for Eisenhower Medical Center in Rancho Mirage, California, and started his career in Cleveland, Ohio with Orion Consulting/New Health Management. David received his BS in Finance from the University of Colorado (Boulder) and his MBA with a focus in health care management from Cleveland State University.

On a personal note, David has been married to his best friend for 27 years. They have three children and two grandchildren. David enjoys skiing in the Rockies, reading a good sci-fi or action thriller, golfing whenever he can and travel with friends and family.

SPONSORS

DIAMOND

PLATINUM

GOLD

SILVER

SUPPORTING